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1. Introduction 
Around 24 million of people worldwide have some kind of dementia, and most of them are 
diagnosed to suffer from Alzheimer's disease (AD). In fact, every seven second a new case of 
dementia is identified, arriving to the rate of 4,6 new million cases per year. It is expected 
that by 2040 over 80 million of people will be affected. Neurological diseases are therefore a 
major public health problem due to the rise in the aging population, only in Europe these 
disorders cover approximately 35% of the burden of all diseases. In economical terms, brain 
diseases in Europe cost a total of 386 billion of euros per year, with an average of 829€ per 
inhabitant. AD and other dementias represent the second-leading cause of brain disorders 
after affective ones and equal with addiction diseases (Wittchen and Jacobi, 2005). 
Altogether dementias, and in particular AD represent a huge socio-economical impact, not 
only regarding the cost from the pharmacological point of view but also familiar cares 
which increase in an alarming rate in the last stages of the disease. Worthy to mention is the 
role of the family during the progression of this kind of diseases, relatives have to watch the 
patient every moment above all during the first lapses of memory and some of them need 
psychological help to assume the situation and the change in their lifestyle. 
The incidence and prevalence of this group of diseases explain the need to understand 
mechanisms underlying dementia to uncover early and discriminative diagnostic markers 
as well as new therapeutic targets in order to improve the quality of life of these patients 
and the efficacy of the treatements. For these reasons research in AD is currently considered 
as a priority. At this time, the pharmacological treatments available aim to enhance the 
cognitive impairments once the disease is diagnosed, only cholinesterase inhibitors and one 
NMDA receptor antagonist are commercialized. Despite these products can alleviate the 
symptomatology, they are far away to constitute an effective remedy to cure or prevent the 
deleterious effect of the disease. In line of these observations, methods for improving 
diagnosis are needed, the search of biomarkers and neuroimaging techniques might help to 
support clinical diagnosis and detect the disease in the earliest stages. The identification of 
potential genetic and environmental risk factors as well as protective ones may provide a 
new window of action even if interventions at this level are more complex and controversial 
(Ballard C et al., 2011). 
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Despite AD covers between 60 to 80% of the causes of dementia, there are many other 
causes: vascular dementia, mixed dementia, dementia with Lewy bodies, Parkinson's 
disease, frontotemporal dementia, Creutzfeldt-Jakob disease, Huntington's disease and 
Wernicke-Korsakoff syndrome are some of them (http://www.alz.org). Current available 
diagnosis of AD is based mainly on the severity of cognitive impairments. However, even 
with the help of several neuroimaging techniques it is not simple to discriminate among AD 
and other age-related cognitive impairments. Unfortunately only an accurate diagnosis of 
AD can be reached after autopsy examination. Nonetheless, it is necessary and desirable to 
incorporate new biomarkers that are more sentitive, specific and may facilitate the diagnosis 
not only among the different disorders but also to discern the clinical progression (Seshadri 
S et al., 2011). 
As it is described along this chapter the field of proteomics provides a powerful tool, which 
might enable to identify new proteins for early diagnostic and potentially therapeutic 
targets in AD. It is also remarkable the mandatory use of animal models in order to 
elucidate new pathways involved in the pathogenesis. Transgenic mouse models provide 
biochemical modulable approches where in a dependent or independent way several 
parameters can be studied (Sowell RA et al., 2009). 
2. Historical input of proteomics to Alzheimer´s disease and other 
neurological disorders 
AD is a progressive neurodegenerative disorder that leads to dementia. This pathology is 
characterized by two histopathological features: senile plaques and neurofibrillary 
degeneration (NFD) (Alzheimer A et al., 1907). Senile plaques are an extracellular 
accumulation of amyloid deposits formed by Aβ peptide. Aβ is a small 39 to 43 amino acid 
peptide produced by the complex catabolism of a type I transmembrane glycoprotein 
precursor named amyloid precursor protein (APP). Despite in AD only 1% of the cases have 
a familial history or inherited, most of the mutations described are related to APP, presenilin 
1 (PSEN1), PSEN2 and SORL1 genes. Indeed the amyloid hypothesis of AD is considered 
almost like a dogma regarding the number of therapeutical research focused on this event 
(Hardy J and Selkoe DJ 2002). NFD has been consistently found in many neurodegenerative 
diseases among which the most prevalent is AD. Others include corticobasal degeneration 
(CBD), dementia pugilistica, fronto-temporal dementia with parkinsonism linked to 
chromosome 17 (FTDP-17), head trauma, Down syndrome, postencephalic parkinsonism, 
progressive supranuclear palsy (PSP), myotonic dystrophy (DM) and in Pick´s disease (Buee 
L et al, 2000). Nonetheless, the vast majority of studies have been performed in AD. 
At the molecular level NFD corresponds to the aggregation of hyper- and abnormally 
phophorylated Tau proteins into filaments referred to paired helical filaments (PHFs) (Brion 
JP et al., 1985; Ihara Y et al., 1986). The spatiotemporal distribution of NFD in the diseased 
human nervous system is well correlated with the clinical expression of cognitive deficits 
(Delacourte A et al., 1999). However, there is a long and clinically silent period during 
which the lesions slowly developed and progress in several brain areas and are yet clinically 
silent. Neuropathological studies show that NFD is already detected in locus coeruleus of 
some people under 30. Moreover, the entorhinal cortex of non-demented individuals aged 
over 50 years, and the hippocampus are also often affected. During the earliest stages of AD 
with cognitive functions impairment, NFD is quite specific, spreading from the 
hippocampal formation to the anterior, inferior, and mid temporal cortex. NFD follows a 
www.intechopen.com
 
The Microtubule-Dissociating Tau in Neurological Disorders 293 
stereotyped, sequential and hierarchical pathway. The progression is categorized into ten 
stages according to the brain regions affected: transentorhinal cortex (S1), entorhinal (S2), 
hippocampus (S3), anterior temporal cortex (S4), inferior temporal cortex (S5), medium 
temporal cortex (S6), polymodal-association areas (prefrontal, parietal inferior and temporal 
superior) (S7), unimodal areas (S8), primary motor (S9a) or sensory (S9b, S9c) areas and all 
neocortical areas (S10). Up to stage 6, the disease can be asymptomatic (Figure 1).  
 
 
Fig. 1. NFD evolution in AD and cognitive decline. Watches represent the perception of the 
objects depending on the stage of the disease. 
Despite tau proteins are heat stable, acid stable and very soluble in its native unfolded form 
(Cleveland DW et al., 1997), numerous methods have been used in order to dissect tau 
aggregates. First, PHFs in AD were initially observed by electron microscopy in 1963 (Kidd 
M. 1963). Then, in chronological order, Selkoe and collaborators described in 1982 a partial 
purification of PHFs from human brain tissue. PHFs showed a small solubility in urea, 
guanidine and detergents as sodium dodecyl sulphate (SDS), representing an example in 
neurons of a rigid intracellular polymer maybe as a consequence of covalent bonds that 
avoid a molecular separation by gel electrophoresis (Selkoe DJ et al., 1982). The first 
commonly used PHF preparation is that described by Nukina N and Ihara Y in 1985 and 
consists to have PHF in Sarkosyl insoluble fractions. Further purification of Sarkosyl pellets 
was described by Hasegawa and collaborators in 1992. Pellets were suspended in a small 
volume of 50 mM Tris-HCI (pH 7.6), and dissolved with 6 M guanidine HCI for further 
purification. The guanidine HCI suspension was centrifuged at 500,000 X g for 30 min on a 
TL100.3 microcentrifuge (Heckman). The supernatants were treated with iodoacetate after 
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reduction and fractionated on a TSK gel G-3000 SW column (7.8 X 600 mm, Tosoh) 
equilibrated with 6 M guanidine HCI in 10 mM phosphate buffer (pH 6.0), at a flow rate of 
1.0 ml/min. The TSK fractions contain full-length tau with unusually slow mobilities in 
SDS-PAGE. The second commonly used preparation is that of Greenberg and Davies: about 
50% of PHF immunoreactivity can be obtained in 27,200 x g supernatants following 
homogenization in buffers containing 0.8 M NaCl. Further enrichment was made by taking 
advantage of PHF insolubility in the presence of zwitterionic detergents and 2-
mercaptoethanol, then removal of aggregates by filtration through 0.45-microns filters, and 
sucrose density centrifugation. PHF-enriched fractions contained proteins of 57-68 kDa that 
displayed the same antigenic properties as PHFs. The next stept was to develop an amino 
acid sequencing technique for PHFs combining a purification and solubilization procedure. 
After electrophoresis the insoluble fraction presented identical amino acid composition 
despite successive electrophoresis. Electron microscopy confirmed no changes in PHFs 
structures for the insoluble fraction even after electrophoresis. Moreover, this insoluble 
fraction displayed immunoreactivity against purified PHFs antibodies. Almost totally 
solubilization for the insoluble part was achieved by increasing the time of electrophoresis 
till almost 35 h showing one predominant band at 66 kDa and three additional bands 
between 50 and 70 kDa (Vogelsang GD et al., 1990).  
Further studies based on the soluble and insoluble fractions after sucrose density gradient 
showed tau amino-terminal epitopes were more abundant in the soluble part and almost 
nonexistent in the insoluble one, in the other way around carboxy-terminal epitopes were 
observed in both fractions. These last observations pointed out the proteolytic degradation 
involved tau amino-terminal region and not in the carboxy-terminal part in the formation of 
PHFs in NFD (Ksiezak-Reding H et al., 1994). 
Apart from characterization of PHFs from the solubility point of view, the development of 
additional approaches as electronic microscopy has definitely contributed to elucidate their 
ultrastructure. For instance, scanning transmission electron microscopy (STEM) provides 
accurate measurements of samples purified from human tissue and allows quantitave 
comparison between aggregated and dispersed population (Ksiezak-Reding H et al., 2005). 
Information regarding the filamentous conformation contributes to uncover the 
phosphorylation role in their formation. PHFs display ultrastructural different 
characteristics in AD and other neurological disorders. One possible classification is 
according to the straight or twisted filaments, based on the width of them along the length. 
Particularly twisted filaments are more abundant in AD and straight ones in PSP and both 
can be easily differentiated in CBD.  
Along this section it has been described the main attempts to solubilize PHFs in order to 
clarify their composition, structure and their role in the aetiology in neurodegenerative 
disorders, mainly focused on AD. It can be considered that these were the first proteomics 
contribution to uncover the NFD progress involved in the cognitive impairments and loss of 
memory. In the next section we will discuss about the more modern and current proteomics 
methods and their application in the field of neurodegeneration. 
3. Proteomic methods 
Proteomics is the study of proteome, which are the whole set of proteins expressed by a genome 
of a cell, tissue or organism. So the analysis of a proteome is any study directed to level 
expression, degradation or post-translational modifications of proteins. Proteomics methods 
enable the identification and composition of these proteins from diverse biological samples.  
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Proteomics field may be divided into two main areas: protein profiling and functional 
proteomics. Profiling proteomics provides all the proteins of a sample, level of expression 
and global profile. At a functional level proteomics afford a lot of new and challenge 
pathways that may be related to disease aetiology and development of the symptoms. 
Identification of theses pathways and protein changes in expression or post-translational 
modifications might lead to a novel window of therapeutical targets. A better knowledge of 
the evolution in these proteins during the pathological process may also increase the 
accuracy for an early clinical diagnosis. In that sense, the most challenging discovery would 
be to find characteristic biomarkers of each disease and their modifications concerning the 
worsening of the symptoms during the progress of the illness. The study of the human brain 
proteome is one of the most challenging aspects in science during the last decades. Brain 
functions and their involvement in process like memory, behavior, and emotions in 
physiological as well as in pathological orchestration remain far from understood. 
Independently where samples come from tissue, cells or body fluids as cerebrospinal fluid 
(CSF), the extraction of proteins is the caput anguli in all experiments. It is mandatory to 
establish the brain area, neuronal population or affected region, which is object of study. 
Moreover, thanks to the enormous protocols available for protein isolation, it is possible to 
achieve material enough from subcellular regions such as mitochondria or lipid rafts. 
Nowadays it is very useful and worldwide use the microdissection that enables to select a 
homogenous tissue or neuronal population, using a laser-dissecting microscope. 
Noteworthy that proteome analysis is not always reliable, not only because of changes in the 
expression profile as a consequence of genomic modifications, but also due to variability in 
extraction protocols and the quality of the sample after autopsy. 
Proteomics analyses include two key steps, on one hand the separation and isolation of the 
protein to study and on the other hand the identification of proteins by mass spectrometry. 
In addition to separation and identification methods, there are also many well characterized 
technology to quantify protein as 2D differential gel electrophoresis (2D-DIGE), iTRAQ-
Isobaric Tags for Relative and Absolute Quantification or SILAC-Stable Isotope Labeling by 
Amino Acids. Proteomics and bioinformatic developing technologies run in pararell since it 
is not possible to achieve hight standards in protein quantification and reliable identification 
if softwares do not allow discriminating among the possible variants and erasing the 
background that all the experimental conditions generate. Filters and integrators constitutes 
a general paradigm for signal detection in biology (Ideker T et al., 2011). In any case the 
researcher owns the most powerful weapon that is the capacity to assume the feasibility of a 
biological data, it means how the system is constructed and the functions carried out. 
Software enables to have update database easily accessible on internet including genome, 
transcriptome, metabolome, interactome and of course proteome (Brewis IA and Brennan P, 
2010). There are several databases available for the research community dedicated to the 
analysis of protein sequences and structures, some of them are NCBI Peptidome, Expert 
Protein Analysis System (ExPASy), PeptideAtlas, the PRoteomics IDEntifications database 
(PRIDE) and Global Proteome Machine Database (GPMDB) (Vizcaíno JA et al., 2010). 
3.1 Identification methods 
Mass spectrometry (MS) is one of the most widespread developed analytical technique in 
biological sciences. Analysis of the amino acid sequence, tridimensional structure and 
characterization of post-translational modifications has allowed elucidating protein 
functions. Despite it is not the aim of this chapter it is useful to say that MS is also used in 
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DNA studies (Murray KK, 1996). MS is nowadays used in a large number of fields including 
from biochemistry to genome studies (Pandey A and Mann M, 2000). In combination with 
separation techniques, MS due to its sensitivity and speed may have an important role in 
identifying and monitoring biomarkers in physiological fluids as well as in drug discovery. 
This approach enables to identify therapeutic targets present at low concentrations in 
complex biological samples. 
From the theorical point of view MS is not a measure of the mass, indeed it is a mass-to-
charge (m/z) ratio of gas-phase ion. The values should be represented in terms of Daltons 
(Da) per unit of charge and the unit in the International System are Kilograms per Columb. 
In spite of the information obtained with this analysis is directly associated with the 
molecular weight and amount of protein, the results offered the possibility to acquire 
additional information as structural disposition (Zellner M et al., 2009). 
MS are composed by three different parts: an ionization source, a mass analyser and a 
detector. The development of this technique is strengthly linked to the introduction of new 
and more sensitive components in these equipments.  
Ionization source 
Ionization can be defined as any process by which electrically neutral compounds are 
converted into ions (electrically charged atoms or molecules). Samples must be ionised and 
transferred to the gas phase, as a consequence of this step sample is destroyed. Classically 
ionization takes places in two separate steps, one in which the sample is volatilized and 
another one where it is ionized. The improvement in ionization methods permits to ionise 
large, non-volatile and thermally labile biomolecules and convert them into a gas phase 
without dissociation (Chait BT and Kent SB, 1992). The importance of these improvements 
was awarded in 2002 by the Nobel Prize in Chemistry "for the development of methods for 
identification and structure analyses of biological macromolecules" with one half jointly to 
John B. Fenn and Koichi Tanaka "for their development of soft desorption ionisation 
methods for mass spectrometric analyses of biological macromolecules" and the other half to 
Kurt Wüthrich "for his development of nuclear magnetic resonance spectroscopy for 
determining the three-dimensional structure of biological macromolecules in solution". 
Electrospray ionization (ESI) and matrix-assisted laser desorption/ionization (MALDI) are 
the most worldwide ionization sources used nowadays. 
In ESI the ion transfer from the solution to the gas phase ocurrs at atmospheric pressure 
(Zellner M et al., 2009). It is a process by which an aerosol is generated between two 
electrodes through a capillary held at a high potential (classically 3–4 kV), ions are separated 
of the solvent and get into the mass analyser. This method does not present a limit of size of 
the molecule to ionize and it can be easily coupled to MS and liquid separation techniques. 
Another variation of ESI is nanospray that owns a higher ionisation efficacy and it is less 
sensible to salt contamination. ESI might be the technique of choice for the design and 
development of quenchers against α,β-unsaturated aldehydes that are strongly associated 
with the oxidative stress (Beretta G et al., 2008), it has been used for instance to identify a 
human T-cell activation RhoGTPase-activating protein in a high frequency electromagnetic 
field irradiation model to induce AD features (Chang IF and Hsiao HY, 2005), to identify 
phosphorylation sites on tau (Reynolds CH et al., 2008) and analysis of phospholipids in 
CSF of AD patients (Kosicek M et al., 2010). 
MALDI is maybe the most common ionization source used at the present time in proteomics 
era. Above all because it can be easily coupled to time-of-flight (TOF) mass analysers. 
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MALDI was introduced by Hillenkamp and Karas and currently is like ESI a suitable 
technique to the study of complex biological samples (Hillenkamp F and Karas M, 1990). 
MALDI produces mostly singly charged ions by a pulsed-laser irradiation. Moreover, 
MALDI owns a really high sensibility with almost no sample wasting and no desalting 
process is necessary since it works at physiological concentration of salts. In addition, 
MALDI requires relatively cheap equipment and quite easy to handle. MALDI TOF mass 
spectrometry is the technique of choice for protein identification separated by two-
dimensional gel electrophoresis. MALDI TOF is widely used in the study of AD in different 
cellular compartment as synaptosomes proteins (Yang H et al., 2011), Aβ isoforms and their 
effect on tau phosphorylation in transgenic mouse model overexpressing Aβ1-40 and Aβ1-
42 (Mustafiz T et al., 2011), evalutation of a vaccine specifically targeting the pathological 
amino-truncated species of Aβ42 that induces the production of specific antibodies against 
pathological Aβ products (Sergeant N et al., 2003), the possible role of heavy metal as copper 
(II) in the formation of PHFs (Zhou LX et al., 2007), identification of lipids containing in the 
PHFs from human brain as phosphatidylcholine, cholesterol, galactocerebrosides and 
sphingomyelin (Gellermann GP, et al 2006), identification of post-translational changes of 
proteins involved in AD as JNK-interacting protein 1 that is hyperphosphorylated following 
activation of stress-activated and MAP kinases (D'Ambrosio C et al., 2006), enrichment of 
more truncated glycans in PHFs (Sato Y et al., 2001) and decrease in the expression of M2 
acetylcholine receptor (Zuchner T et al., 2005) are some examples. 
Mass analyser 
Once ions have been originated they are transported to the mass analyser region and 
separated according to their m/z. The election of one o the type of analyser will depend on 
their resolution, when more resolutive high capacity to defferentiate two close signals. Mass 
analysers available in the market are electric- and magnetic-field, depending on the way to 
separate the ions. The choise among them will depend on the application needed and the 
budget since each analyzer type has its strengths and weaknesses. Mass analysers systems 
are Quadrupoles, Sectors, Fourier transform cyclotrons and TOF. Quadrupole analysers are 
normally coupled to ESI ion sources and TOF analysers are often used with MALDI ion 
sources. Anyway, hybrid systems are also employed as ESI–TOF and MALDI–QTOF. 
TOF spectrometer separates ions based on their velocity with a theorical mass gap 
unlimitated. TOF consists basically of a flight tube in high vacuum where ions are 
accelerated with equal energies and fly along the tube with different velocities. The flight 
time is related to the m/z values of the ions. The combination of high m/z range and 
compatibility with pulsed-ionization methods has made TOF the most commonly used 
analyser for MALDI experiments. 
In Peptide Mass Fingerprinting approach gel-separated proteins are digested in the gel with 
a site-specific proteinase as trypsin (Hellman U et al., 1995). Then MS measurement of the 
cleavaged proteins is performed generally by MALDI TOF equipment. Finally Fingerprint 
peptides are compared to databases in which protein sequences have been already digested 
with the same proteinase. This is the method of choise for highthroughput identification of 
numerous samples. Moreover, robotic systems launched onto the market make possible the 
automation from detection spot in the gel till MS identification (Henzel WJ et al., 1993). 
Tandem Mass Spectrometry (MS/MS) is another identification method predominantly 
suitable for analysing complex samples and a routine method used in research. This 
technique permits the identification of unkown proteins by sequencing their peptides. 
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MS/MS involved two steps of MS. In the first analyser ions with a desired m/z are 
separated (product ions) from the rest of the ions coming from the ionization source, and in 
the second type of analyser the mass spectrum is measured. Furthermore, MS/MS 
experiments improve the ratio signal/noise facilitating the resolution. 
The product ions can be used to find out the primary structure of the peptide but nowadays 
most efforts are directed towards identification of post-translational modifications. In the 
case of tau protein is particulary special, since phosphorylation provides an additional 
negative charge to the sample. This fact complicates the analysis by MS because of detection 
of phosphopeptides is highly dependant on the equipment used as well as the software 
applied to analyze the spectra. Moreover, the existence of several adjacent serine or 
threonine residues allows MS/MS not to attribute the exact position of a phophate group as 
a result of the fragmentation of the peptide data.  
The team of Hasegawa performed the earliest application for identification of Tau into PHFs. 
They used different fractions: purified PHF-tau, AD-soluble tau, or normal tau treated or not 
with alkaline phosphatase. The digests were applied to a Superspher Select B column (2.1 X 
125 mm, Merck) and eluted with a linear gradient of 4-48% acetonitrile in 0.1% trifluoroacetic 
acid in 20 min at a flow rate of 0.2 ml/min. Amino Acid Sequence and Mass Spectrometric 
Analyses of the API Peptides-Fractionated peptides were sequenced on an Applied 
Biosystems 477A Protein Sequencer equipped with an on-line 120A PTH Analyzer or on an 
Applied Biosystems 473A Protein Sequencer. Mass spectral analysis was performed on a PE-
SCIEX API 111 Hiomolecular Mass Analyzer (triple-stage quadrupole mass spectrometer) 
equipped with a standard atmospheric pressure ion source. Detailed comparison of peptide 
maps of PHF-tau and normal tau before and after dephosphorylation pointed to three 
anomalously eluted peaks which contained abnormally phosphorylated peptides, residues 
191-225,226-240,260-267, and 386-438, according to the numbering of the longest tau isoform. 
Protein sequence and mass spectrometric analyses localized Thr-231 and ser-235 as the 
abnormal phosphorylation sites and further indicated that each tau 1 site (residues 191-225) 
and the most carboxyl-terminal portion of the protein (residues 386-438) carries more than two 
abnormal phosphates. Ser-262 was also phosphorylated in a fraction of PHF-tau. Modifications 
other than phosphorylation, removal of the initiator methionine, and Nu-acetylation at the 
amino terminus and deamidation at 2 asparaginyl residues were found in PHF-tau, but these 
modifications were also present in normal tau (Hasegawa et al., 1992). 
NMR spectroscopy is an alternative to MS and it has been used to uncover physiological 
and pathological roles of tau protein. However, this is challenging since tau protein has 441 
amino acids and an unfavorable amino acid composition. Quantification of phosphorylated 
tau samples is complex and studies are being performed in vitro using recombinant kisases 
(Landrieu I et al., 2010). 
3.2 Separation methods 
Analysis of a sample is always a challenge, it depends on the origin and of the aim of the 
experiment. Separation of the components of a sample offers the possiblility to establish a 
pre-selection and to perform a study concerning parameters as molecular weight (MW) and 
isoelectric point (pI). The separation methods available today have the enormous advantage 
that they can be coupled to other quantification techniques, including in this way not only 
the identification of the protein of interest, but also it relative amount compared to the 
control conditions. During this section we will converse abouth two separation approaches 
such as bidimensional electrophoresis and liquid chromatography. 
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3.2.1 Two-dimensional gel electrophoresis in AD brain 
Two-dimensional gel electrophoresis (2D) is one of the most often-used separation methods 
in proteomics since first description by O´Farrell PH in 1975. This approach combines two 
electrophoretic methods: in the first dimension proteins are separated on an immobilized 
pH gradient strip with isoelectric focusing and migrate to the point on the strip at which 
their net charge is zero or pI, and in the second dimension or SDS-PAGE, proteins are 
separated according to their MW and thus isolating isoforms and isovariants of a certain 
protein.  
This approache provides two kinds of information depending on the aim of the study. On one 
hand it can offer the global proteome profile with a high resolution containing nearly one 
thousand protein spots. However, the main limitation of the 2D is that several replicates of the 
same gel should be performed in order to reach statistically differences. The lack of a loading 
control makes complicated to rule out between differences in protein expression and loading 
variability among gels (Molloy MP et al., 2003). In addition, absence of an internal control for 
loading makes this approche very hand variable. On the other hand, this method is quite 
indicated if qualitative analysis is pointed out, ie if post-translational modifications are 
searched, the performance of a 2D western blot for two different conditions may supply 
changes in pI and /or MW. More specifically in the case of the tau protein, this method might 
give interesting data about the acidification or alkalinization as a consequence of 
phosphorylation process, which is the most common post-translational modification. For 
instance in figure 2 is shown 2D western blots for human total tau and phospho dependent 
AD2 antibodies in AD brain sample. Remarkably in the acidic part of the membrane it can be 
observed the characteristic triplet of phosphorylated tau (2A) in AD (60,64,69 kDa), while in 
the basic region all the tau isovariants dephosphorylated with postmorten delay are revealed 
(2B). Interestingly, in a recent study of our group it has been shown that the use of 2D may 
provide evidence that tau mutations dysregulate tau phosphorylation status. This event could 
be one of the first steps in the NFD cascade (Bretteville A et al., 2009). 
 
 
Fig. 2. 2D profiles of phospho-tau (A) and total tau (B) antibodies. Number 1 represents the 
hyperphosphorylated isovariants of tau while number 2 shows the low phosphorylated 
ones. Number 3 displays the native form of tau (Fernandez-Gomez FJ et al., personal 
unpublished data). 
3.2.2 Quantitative proteomics by Two-Dimensional Differential Gel Electrophoresis 
(2D-DIGE) 
2D-DIGE method is based on the same principle as “classical” 2D. The main differences rely 
on the fact that proteins are labeled with fluorescent dyes and all the samples are separated at 
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the same time in the same gel reducing spot pattern variability and the number of gels in an 
experiment. The reduction in number of gels during the manipulation increases the cost 
effectiveness and accurate spot matching. 2D-DIGE presents also the advantage that it is a 
quantitative approche since each protein spot has its own internal standard (IS), which ensure 
that the differences found are real and not due to a gel-to gel variation. Moreover, 2D-DIGE is 
a very sensitive technique with a detection threshold of around 1 femtomole of protein (Gong 
L et al., 2004). In the minimal labeling proteins are stained by cyanines, these dyes has a N-
hydroxysuccinimidyl ester reactive group which forms a covalent bond with the epsilon 
amino group of the lysine in proteins via an amide connection. The single positive charge of 
the cyanine replaces the single positive charge of the lysine and the pI of the protein is not 
altered. This labeling reaction is minimal since only affects between 1-3% of the lysine 
residues. Using different cyanines dyes as Cy2, Cy3 and Cy5 covalently coupled to one protein 
sample each, then they can be mixed and loaded in the same gel (Viswanathan S et al., 2006) as 
it is shown in figure 3. A pool of all the samples is labeled with Cy2 and in this way the 
loading variability among gel is reduced to about 7% (Tannu NS et al., 2006). Differences will 
be observed after measurement of the intensity of the fluorescence for each cyanine. The 2D 
analysis software using the IS achieves a fast detection of less than 10% of differences between 
samples with more than 95% of statistical confidence (Gharbi S et al., 2002). 
 
 
Fig. 3. Cy2, Cy3 and Cy5 merged (A) Cy2 labels IS (B) Cy3 pool of control (C) and Cy5 pool 
of AD samples (D). The software overlaps Cy2, Cy3 and Cy5 in order to establish the 
statistical differences among the replicates of the gels for each spot (Fernandez-Gomez FJ et 
al., personal unpublished data). 
Despite the fact that it is far less used, there is in the market another 2D-DIGE method called 
saturation labeling where only two cyanines are used. Cy3 is the pool of samples and it 
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constitute the IS and Cy5 is the sample object of study. In this technique saturation dyes 
have a maleimide reactive group, which is designed to form a covalent bond with the thiol 
group of cysteine residues on proteins via a thioether linkage, and a high dye-to-protein 
labeling ratio is required. This type of labeling approach tries to label all available cysteines 
on every protein. This method has the main inconvenient that only one sample can be 
loaded in a gel apart from the IS and not two sample like in the minimal labelling. The big 
adventage is that cyanines offer great sensitivity with detection over 5 orders of magnitude 
(Shaw J et al., 2003). 
The main limitation inherent to 2D method is that the gap of separation is among pH 3-10. 
As a consequence of this, poor solubilisation of highly acidic and basic proteins is reached. 
Proteins strongly attached to the biological membranes and samples with high 
concentration of salt own difficulty to be separated by isoelectric focusing, for this reason it 
is strong recommended to perform a purification step previous to the first dimension. 
2D-DIGE application accomplishes one of the new perpectives in the medical research. This 
approach is been widely used for many studys in neurodegenerative disorders including 
AD. 2D-DIGE has been utilized in the search for biomarkers in CSF in amyotrophic lateral 
sclerosis (Brettschneider J et al., 2008), in Creutzfeldt-Jakob disease (Brechlin P et al., 2008) in 
AD patients (Maarouf CL et al., 2009), in frontal cortex brain samples of AD (Müller T et al., 
2008) and in animal models. 
3.2.3 Quantitative proteomics by Liquid Chromatography linked to Mass Spectrometry 
(LC-MS) 
Liquid chromatography (LC) consist in separating proteins eluted from a LC column after 
the peptides are enzimatically digested, then they can be measured by MS. LC separation 
takes place when the sample components interact to a different extent with a mobile or 
stationary phase and elute at different times from this system. Normally several 
chromatographic systems are used in order to achieve a high resolution separation since 
only one system may not separate the complex mixture of peptides successfully. Then 
eluted fractions are undertaken to MS. The biggest adventage of LC coupled with MS is that 
this system presents a high-speed identification of the sample in an automatically way 
avoiding interindividual variability (Zellner et al., 2009). LC-MS is not a quantitative 
method per se, the peptide products coming from the proteolytic cleavage may alter the 
intensity of the signal in MS analysis due to their physicochemical characteristics. In order to 
discard this problem the use of stable isotopes has had a wide acceptance in the science 
community to achive accurancy in the quantification. The approach is based on the idea that 
a stable isotope-labeled peptide is chemically identical to its native counterpart and behaves 
identically during fractionation, digestion, chromatographic and MS analysis, but is 
distinguishable in a MS due to the mass diference. The ratio of signal intensities for the 
labeled and unlabeled peptide pairs provides an accurate measure of relative abundance of 
peptides from different samples. Stable isotopic tags can be introduced onto selective sites 
on peptides via metabolically, chemically, enzymatically, or provided by adding synthetic 
peptide standards to the sample. Strategies for isotope-based quantitative proteomics can be 
divided into two groups, depending on whether the isotopic tag is incorporated in vitro 
during sample preparation (iTRAQ, ICAT) or in vivo (SILAC) (Colucci-D´Amato et al., 2011). 
Isotope Coded Affinity Tagging (ICAT) reagents consist of an affinity biotin tag for selective 
purification, a linker that incorporates stable isotopes and an iodoacetamide group that 
specifically reacts with free thiol of cysteines. Proteins from two different samples are 
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labeled with either light or heavy ICAT reagents obtaining a distinctive mass (eight or nine 
Da). To minimise the error, the labeled mixture of protein samples are combined, digested 
with protease to peptides and fractionated by multidimensional chromatography and 
analysed by LC-MS. The ratios of signal intensities of differentially mass-tagged peptide 
pairs are quantified to determine the relative levels of proteins in the two samples. An 
interesting application of this technique is for the redox proteomic since ICAT labels 
cysteine residues (Sethuraman M et al., 2004). However, this method is not suitable for 
quantifying proteins that do not contain enough residues of cysteine and it presents the 
limitation that only two samples can be done at once (Shiio Y and Aebersold R, R 2006). For 
this reason this approach is limited for studying of post-translational modifications and 
splice isoforms. 
Another amino group-based isotope labeling approach is isobaric tagging for relative and 
absolute protein quantification (iTRAQ). Unlike ICAT this method allows identification and 
quantification as well as comparison of up to eight conditions at the same time. This strategy 
has been developed in order to overcome the limitations of the previous one, so this method 
targets the peptide N-terminus of the residues (Ross PL et al., 2004). The iTRAQ reagent 
consists of a reporter group that is a tag with a specific mass in each individual reagent and 
a balance group to ensure that the reporter and balanced groups remain invariant without 
changing the mass. After collision-induced dissociation reporter ions spectra is correlating 
with the protein-sequence database and relative quantification of proteins with high 
accuracy is reached (Gevaert K et al., 2008). 
Stable Isotope Labeling by Amino Acids (SILAC) is a metabolic stable isotope labeling 
during cell growth and division in bacteria and afterwards was adapted to amino acids in 
cell cultures (Ong SE et al., 2002). SILAC is a simple procedure in which natural variants of 
essential amino acids are replaced by deuterated, carbon-13 or more currently by nitrogen-
15. Using nitrogen-15 the number of incorporate labels is defined and not dependent of the 
number of carbons that constitute the peptide sequence, this facilitates the analysis of the 
results. The advantage of this method relies on it accurate quantification since stable 
isotopes are incorporated very early in the sample. The main inconvenient of this technique 
is that isotopes can only be incorporated during protein synthesis. This is a huge limitation 
for the study of CSF and human brain tissue taking into account that neurons are post-
mitotic cells (Bantscheff M et al., 2007). Despite this handicap SILAC is a powerful tool to 
study cellular pathways as polyubiquitin involment in the aetiology of AD (Dammer EB et 
al., 2011), neuroinflamation (McGeer EG and McGeer PL, 2010), reactive microglia (Klegeris 
A et al., 2008), neurotrophin signaling (Zhang G et al., 2011), oxidative stress (Akude E et al., 
2011), TDP-43 proteinopathy in frontotemporal lobar degeneration and amyotrophic lateral 
sclerosis (Seyfried NT et al., 2010) mitochondrial alterations in dopaminergic cells (Jin J et 
al., 2007) and modulation of ion channels by phosphorylation (Park KS et al., 2006). 
Other methods for protein quantification are multiple reaction monitoring (MRM) that has 
been successfully used for low abundant proteins in plasma (Anderson L and Hunter CL, 
2006) and phosphopeptides quantification (Lange V et al., 2008). The absolute quantification 
of proteins (AQUA) technology uses a known quantity of heavy isotope labeled peptides as 
IS added as soon as possible in the analytical process (Kettenbach AN et al., 2011). 
3.2.4 Surface-enhanced laser desorption/ionization mass spectrometry 
Surface-enhanced laser desorption/ionization mass spectrometry (SELDI) method combines 
retention chromatography with MS detection, and it can be used in biological samples such 
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as cancer cells, CSF and tissue lysates. A few microliters of a sample of interest are deposited 
on the chromatographic surface. The protein chip arrays are incubated and then washed 
with a suitable buffer. SELDI protein chip surfaces are uniquely designed to retain proteins 
from complex mixtures according to their specific properties using chromatographic-based 
selectivity. The proteins of interest are captured on the chromatographic surface by 
adsorption, partition, electrostatic interaction or affinity chromatography depending on 
their properties, and analyzed by MS. SELDI is frequently coupled to MALDI-TOF and 
possess the significative advantage that minimal amount of sample is consuming and 
consequently not destroyed. 
The main application of this technique is in the search of biomarker in cancer as well as in 
neurodegenerative disorders. In the field of AD, SELDI has been used to find significantly 
higher levels of amyloid-beta peptides monomer and dimer in the blood of AD subjects 
compare to controls (Villemagne VL et al., 2010) and in CSF the enrichment in Aβ10-40 
paralleled by depletion of the fragment Aβ1-42 seems to be a common event in familial AD 
(Ghidoni R et al., 2009). 
4. Contribution of proteomics to Tauopathies classification 
Classification and characterization of neurodegenerative disorders have been one of the 
biggest achievements in proteomic field. Proteomics enable to separate, identify and study 
protein-protein interactions within the different pathologies. Nowadays the term 
tauopathies includes more than twenty well-characterized diseases. The high resolution 
separations of tau proteins in electrophoretic profiles as well as the immunoreactivity with a 
wide range of antibodies provide substantial information to discriminate among the 
different diseases. Major post-translational modification in tau proteins is phophorylation. 
For this reason vast of studies are focused on the role of this modification in the structure, 
function, pI and signalling pathways of tau proteins during the progression of the diseases. 
4.1 Tau proteins 
Tau (tubulin associated unit) is the major component of PHFs. Weingarten MD et al. described 
this protein for the first time in 1975 as an essential factor for the organization, stabilization, 
and dynamics of microtubules (Weingarten MD et al., 1975). Tau is essentially a neuronal 
phosphoprotein located within the axonal compartment (Butler M and Shelanski ML, 1986). 
Tau is prone to modulate the axonal transport and neuronal plasticity (Sergeant N et al., 2005). 
Recently, it has been established that tau regulates the motility of dynein and kinesin motors 
proteins by an isoform-dependent mechanism. Indeed, the shortest tau isoform lacking exon 2, 
3 and 10 impedes the motility of both kinesin and dynein whereas the longest tau isoforms 
with all exons less affects motor protein motility (Dixit R et al., 2008). Therefore, a modified 
pattern of tau isoform expression/ratio, due to tau aggregation for instance, may profoundly 
affect the axonal transport and could possibly lead to neurodegeneration (Crosby AH, 2003). 
Besides its known role as a microtubule-stabilizer and organizer, tau may exert several other 
functions as signalling pathway in neurons (Ittner LM et al., 2010 and Leugers CJ, 2010) and 
DNA protection under stress stimuli (Sultan A et al., 2011). 
A unique human tau (MAPT) gene is located on chromosome 17 at the band position 17q21. 
The restriction analysis and sequencing of the gene shows that it contains two CpG islands, 
one associated with the promoter region and the other with the exon 9 (Andriadis A et al., 
1992). The human tau primary transcript contains 16 exons and in the adult human brain, 
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alternative splicing of exons 2, 3 and 10 gives rise to six tau isoforms where exon 3 never 
appears independently of exon 2. Alternative splicing is regulated during development and 
differentially between tissues. A single isoform lacking the 3 alternative exons 2, 3 and 10 is 
expressed in the foetal brain. Exon 10 encodes an additional microtubule-binding motif 
numbered R1 to R4. Half of tau proteins contain three microtubule-binding motifs and the 
other halves have four microtubule-binding motifs (figure 4A). Constitutive exons are 1, 4, 5, 
7, 9, 11, 12 and 13 and the start codon is located in exon 1. There are two alternate stop 
codons located either following exon 13 or inside exon 14 (Andreadis A, 2005 and Sergeant 
N et al., 2008). Human brain tau isoforms have a range from 352 to 441 amino acids and a 
molecular weigth between 45 to 65 kDa in polyacrylamide gel electrophoresis (figure 4B). 
Primary sequence analysis of tau protein shows that it can be subdivided in four structural 
regions. The amino-terminal region is acidic and variable, depending on the presence or 
absence of exons 2/3 and a proline-rich domain follows it. The latter is followed by 3 or 4 
imperfect repeat motifs (R1 to R4; see figure 4A) - depending on the presence or absence of 
exon 10 - and corresponding to the microtubule-binding domain of tau. Finally, a short 
carboxy-terminal region is found and it is the basic region of the protein (figure 4C). 
 
 
Fig. 4. Six tau isoforms are presented in human brain. These isoforms differ by the absence 
or presence of one or two 29 amino acids inserts encoded by exon 2 (green box) and 3 (violet 
box) in the amino-terminal part. Exon 3 is always incorporated with exon 2. R2 corresponds 
to the presence of exon 10 (orange box) that encodes an additional microtubule-binding 
motif numbered R1 to R4 in the carboxy-terminal part and they are represented as black 
boxes. (A). Molecular weight in mono-dimensional electrophoresis for the six isoforms of 
tau (B) and tau protein regions corresponding to the full-length isoform (C).  
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The amino-terminal region together with the proline-rich domain is referred to as the 
“projection domain”. This unstructured and negatively charged region detaches from the 
surface microtubules (Hirokawa N et al., 1988) and can interact with the plasma membrane 
or cytoskeletal proteins (Brandt R et al., 1995). Tau may therefore contribute to spacing in 
between microtubule lattice and to the parallel ordered organization of microtubules in 
axons (Chen J et al., 1992). Amino-terminal region of tau also interacts with a growing panel 
of polypeptides including motor proteins such as kinesin-1 (Utton MA et al., 2005) and 
dynactin/dynein complex (Magnani E et al., 2007). All interacting polypeptides constitute 
the interactome of tau and indicate the functions in which tau may be implicated. The 
application of 2D gel electrophoresis method has been used to study tau (Janke C et al., 
1996). The six main isoforms of tau are separated as several isovariants with isoelectric 
points comprised between 9.5 and 6.5 due to the alternative splicing and to post-
translational modifications. The amino-terminal region has a pI of 3.8, proline domain has a 
pI of 11.4 and carboxy-terminal has a pI of 10.8. Regarding to the primary structure, the 
polypeptide sequences encoded by exons 2/3 add to tau acidity, whereas exon 10 encodes a 
positively charged sequence that adds to the basic character of tau. Thus tau is rather a 
dipole with two domains with opposite charge modulated either by post-translational 
modifications or tau proteolysis (Wischik CM et al., 1988). 
Tau stabilizes oligomers of tubulins, it is partially folded while interacting with 
microtubules and it was shown to link laterally protofilaments made of tubulin (Santarella 
RA et al., 2004). NMR investigations showed that residues between Val226 to Glu372 are 
binding to microtubule surface involving the all four repeat binding motifs showing that 
amino- and carboxy-terminal domains do not participate in the binding properties of tau 
to microtubules (Sillen A et al., 2007). Tau mutations like in FTDP may impair the binding 
of tau to microtubules (Delobel P et al., 2002). Regarding the physic-chemical properties of 
tau protein it has been addressed that tau protein owns pro-aggregative motifs called 
PHF6 and PHF6* in its carboxi-terminal region at the level of R2 and R3. The amino acids 
sequence of these motifs (306)VQIVYK(311) and (275)VQIINK(280) are prone to promote 
aggregation by the formation of beta-structure (von Bergen M et al., 2001). This 
aggregation and accumulation of misfolded proteins might have a common cause and 
pathological pathway in several neurodegenerative disorders resulting in neuronal loss 
(Tyedmers J et al., 2010). Several studies have revealed that truncated tau drive NFD in 
vivo (Zilka N et al., 2006) and caspase activation lead to tangles formation (de Calignon et 
al., 2010). 
4.2 Post-translational changes of Tau proteins 
Phosphorylation of tau is instrumental to NFD and it is the main post-translational 
modification in tau isovariants as it was shown by 2D immunoblots (Butler M and Shelanski 
ML, 1986). These data shed light to the impact of tau protein for tau biology. There are 85 
potential phosphorylation sites on the longest brain tau isoform. Phosphorylation sites were 
identified with proteomic approaches as MS, NMR, phospho-peptide mapping and the use 
of site-specific phosphorylation dependent tau antibodies (Hanger et al., 2007). Among them 
around 71 correspond to putative phosphorylation sites in physiological and pathological 
conditions. It is worthy to remark that most of the phosphorylation sites surround the 
microtubule-binding domains in the proline-rich region and carboxi-terminal region of tau. 
Phosphorylation regulates several functions of tau such as its binding to microtubules, the 
axonal transport of tau as well as its interactions with amino-terminal partners’ particularly 
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SH3-containing proteins (Rosenberg KJ et al., 2008). For instance, tau transport along the 
axon is negatively regulated by its phosphorylation by GSK3β leading to a reduced binding 
to kinesin-1 (Cuchillo-Ibanez I et al., 2008). By phosphorylating amino-terminal serines 212 
and 217, GSK3β also reduces the binding of SH3-containing proteins, such as Fyn, PLC-γ1, 
p85α (Reynolds CH et al., 2008). Once tau proteins are phosphorylated they cannot 
polymerize tubulin into microtubules and do not stabilize the latter.  
Tau phosphorylation is mainly regulated through kinases and phosphatases, but other 
enzymes are also involved, such as Pin1 isomerase (Buee L et al., 2000). A total of more than 
20 protein kinases can phosphorylate tau proteins (Sergeant N et al., 2008). This includes 
four groups of protein kinases. (a) Proline-directed protein kinases (PDPKs), which 
phosphorylate tau on serines or threonines that are followed by a proline residue. This 
group includes CDK1 and 5 (Hamdane M et al., 2003), MAPK and several SAPKs (Ferrer I et 
al., 2005). (b) The non-PDPK group includes tau-tubulin kinases 1 and 2, casein kinases 1 
and 2, DYRK1A (dual-specificity tyrosine-phosphorylated and –regulated kinase 1A), 
phosphorylase kinase, Rho kinase, PKA, PKB/Akt, PKC and PKN (Sergeant N 2005). (c) The 
third group includes protein kinases that phosphorylate tau on serine or threonine residues 
followed or not by a proline. GSK (glycogen synthase kinase) 3α and GSK3β and AGC 
kinases (such as MSK1 (mitogen- and stressactivated protein kinase) belong to this group 
and have recognition motifs SXXXS or SXXXD/E and RXRXXS/T respectively (Buée L et al., 
2010). (d) The fourth group corresponds to tyrosine protein kinases such as Src kinases, c-
Abl and c-Met (http://cnr.iop.kcl.ac.uk/hangerlab/tautable). The principal role of tau 
phosphorylation is related to microtubule binding. However, phosphorylation or 
dephosphorylation of tau may also contribute to the cell localization of tau. For instance, 
phosphorylation of tau by GSK3β regulates its axonal transport by reducing its interaction 
with kinesin. In sharp contrast, dephosphorylated tau is located to the cell nucleus and is 
suggested to contribute to nucleolar organization and/or contribute to chromosome 
stability. Mutations in TAU gene lead to a change in the affinity of kinases that 
phosphorylate tau near the site of the mutation. Some mutations like R406W may reduce the 
phosphorylation of tau at Ser404, which is necessary for GSK3-β to phosphorylate tau at 
Ser396 afterwards (Tatebayashi Y et al., 2006). However, this priming putative 
phosphorylation site is not a prerequisite for JNK3 to phosphorylate tau at Ser396. These 
data provide evidence that tau mutations may potentially modify the global phophorylation 
state of tau. 
Abnormal phospho sites on PHF-tau were identified on constitutive exons, such as Ser212–
214 together and Ser422. These three new sites were identified on the alternative sequence 
encoded by exon 2. As tau isoforms expression may be different in subneuronal 
populations, these phospho epitopes would be of interest in identifying such subneuronal 
populations or the laminar distribution of NDF in AD (Delacourte A et al., 1996). 
In normal brains the phospho-epitopes are rapidly dephosphorylate during postmorten 
delay, this effect may be due to the drop in ATP and inactivation of phophatases. However, 
in AD brains this dephosphorylatyon does not occur. Some of the hypotheses are that 
aggregation of tau proteins into filaments render them inaccessible to phosphatases, 
phosphatases are not activated any more or their activity is suddenly decreased. 
Other post-translational modification of tau proteins is O-glycosylation. O-glycosylation 
results from the attachment of a sugar on the hydroxyl radical of serine or threonine residue 
in the vicinity of the proline-rich domain. Glycosylation decreases tau phosphorylation by 
CDK5, PKA and and GSKβ, probably due to a competition between phosphorylation and 
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glycosylation for the same sites. In fact, tau proteins from AD brains present abnormally 
glycosylation in comparison with controls. Using a recombinant O-GlcNAc modified tau, 
MS has mapped O-GlcNAc on tau at Thr-123, Ser-400 sites and a third one on either Ser-409, 
Ser-412, or Ser-413 (Yuzwa SA et al., 2011). The identification of these sites may provide 
evidence to elucidate the role of glycosylation in tau function. 
The microtubule-associated protein tau is known to be post-translationally modified also by 
acetylayion. Recent studies reported that tau is acetylated and this acetylation avoids its 
degradation. Tau acetylation impares tau-microtubules interactions and facilitates tau 
aggregation. In fact, specific antibodies for acetylated tau showed an increase in acetylation in 
several Braak stages with the involment of histone acetyltransferase p300 and the deacetylase 
SIRT1 (Min SW et al., 2010). MS provides specific lysines within the microtubule-binding 
domain including lysine 280 (K280) that are main sites of tau acetylation. One model shows 
that K280 is exclusively acetylated in pathological conditions (Cohen TJ et al., 2011). 
4.3 Tau as a bar code for neurodegenerative diseases 
The most obvious pathological event in tauopathies is the presence of aggregates of tau 
isoforms into intraneuronal filamentous inclusions. The evolution in the proteomics era 
allows to establish different physiological and pathological electrophoretical patterns to 
distinguish among the diversity of tauopathies. Comparative biochemistry of tau aggregates 
differs in both isoform phosphorylation and content, which enables a molecular 
classification of tauopathies. In postmorten brain tissue tau proteins are resolved as six 
bands (figure 4B) whereas more acidic hyperphosphorylated isoforms present four bands 
between 60 and 74 kDa depending on the disorder (figure 5). The classification presented 
here is composed by five classes of tauopathies, depending on the type of tau aggregates 
that constitute the bar code for neurodegenerative diseases (Sergeant et al., 2005).  
Class 0: frontal lobe degeneration non-Alzheimer non-Pick 
Frontal lobe degeneration is the second more common presinile disorder that leads to 
dementia after AD. This class is genetically linked to mutations in the progranulin gene 
(Baker M et al., 2006 and Cruts M et al., 2006). Frontal lobe degeneration presents no specific 
neuropathological hallmarks, no tau aggregation and a loss of expression in tau proteins. 
The transactive response (TAR)-DNA-binding protein with a molecular weight of 43 kDa 
(TDP-43), encoded by the TARDBP gene, has been recently identified as a major 
pathological protein of frontotemporal lobar degeneration with ubiquitin-positive and tau-
negative inclusions. It is the most common underlying pathology in frontotemporal 
dementias with and without motor neuron disease. In fact TDP-43 pathology is identified 
till the 50% of AD cases and it is the main component in the amyotrophic lateral sclerosis 
(Wilson AC et al., 2011). This pathology from the clinical point of view is quite similar to 
Pick´s disease. It is characterized by a frontal distribution of morphologic changes involves 
neuronal cell loss, spongliosis and gliosis mainly in the superficial cortical layers of the 
frontal and temporal cortex (Delacourte A et al., 1977). 
Class I: all brain Tau isoforms are aggregated 
Class I is characterized by a pathological tau quartet at 60, 64 and 69 kDa, and a minor 
pathological tau at 72/74 kDa (figure 5). This pathological tau quartet corresponds to the 
aggregation of the six tau isoforms (Sergeant N et al., 1997b and Goedert M et al., 1992). The 
pathological tau 60 is composed of the shortest tau isoform (2–3-10-). The pathological tau 64 
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and 69 are each composed of two tau isoforms: tau isoforms with either the exon 2 or exon 
10 alone compose the pathological tau 64, while the pathological tau 69 is made of tau 
isoforms with either exon 2 + 10 or 2 + 3. The longest tau isoform containing exons 2, 3 and 
10 (2 + 3 + 10) constitutes the 72/74-kDa pathological component, as determined by 2D gel 
electrophoresis coupled to western blotting using exon-specific tau antibodies (Sergeant N 
et al., 1997a). This typical tau profile was first characterized in AD, but now includes nine 
additional neurological disorders AD as cerebral aging (over 75 years), ALS/parkinsonism–
dementia complex of Guam, Parkinson with dementia of Guadeloupe, Niemann–Pick 
disease type C, Postencephalitic parkinsonism, Familial British dementia, Dementia 
pugilisticia, Down’s syndrome and FTDP-17. Using histochemistry, aggregates of this class 
can be observed with AD2 and antibodies against exon 2 and exon 10 (Buee L et al., 2000 
and Sergeant N et al., 2008). 
 
 
Fig. 5. Bar Code for neurodegenerative diseases. Schematic representation of the 
modifications leading to tau proteins aggregation in Tauopathies. Native tau proteins are 
detected as a triplet of bands ranging between 60 and 74 kDa by numerous 
phosphorylation-dependent antibodies. Tau proteins are shown by western blotting as three 
major bands between 60 and 69 kDa, and a minor band at 74 kDa. AD pattern is also found 
in Down’s syndrome, post-encephalitic parkinsonism, ALS/parkinsonism–dementia 
complex of Guam among others (class I). The doublet tau 64, 69 represent the aggregation of 
hyperphosphorylated tau isoforms with exon 10 (orange box) typical for CBP and CBD 
(class II), the exclusion of exon 10 (only black boxes) in hyperphosphorylated tau 
aggregation lead to tau 60, 64 doublet characteristic for Pick’s disease (class III). The 
aggregation of Tau isoforms lacking exons 2 (green box) and 3 (violet box) is found in 
myotonic dystrophy (class IV). 
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Class II: Tau isoforms containing the exon 10 encoding sequence aggregate 
Aggregation of tau proteins with four microtubule-binding domains is the characteristic of 
class II (figure 5). This pathological tau profile is observed in CBD, argyrophilic grain 
dementia, PSP and FTDP-17 due to tau gene mutations (Sergeant N et al., 1999 and Tolnay 
M et al., 2002). PSP, CBD and argyrophilic grain dementia are rare atypical parkinsonism 
disorders. 
Class III: Tau isoforms lacking the exon 10 encoding sequence aggregate 
This class of tauopathies includes Pick’s disease and autosomal dominant inherited FDTP-17 
(figure 5). Pick’s disease is a rare form of neurodegenerative disorder characterized by a 
progressive dementing process. Early in the clinical course, patients show signs of frontal 
disinhibition. Neuropathologically, Pick’s disease is characterized by the presence of typical 
spheroid inclusions in the soma of neurons called Pick bodies. Pick bodies are labeled by tau 
antibodies, with a higher density in neurons of the dentate gyrus of the hippocampal 
formation than in the temporal and frontal cortices. The pathological tau profile of Pick’s 
disease contrasts with that of class II tauopathies, with the pathological tau isoforms 
consisting essentially of the 3R tau isoforms.  
Immunohistologic staining of these aggregates is positive for AD2 and exon 2 antibodies but 
negative for exon 10 antibodies. In addition, aggregated tau proteins in Pick’s disease are 
not detected by the monoclonal antibody 12E8 raised against the phosphorylated residue 
Ser262/Ser356, whereas this phosphorylation site is detected in other neurodegenerative 
disorders. The lack of phosphorylation at Ser262 and Ser356 sites is likely to be related to 
either a kinase is not active in neurons that degenerate in Pick’s disease or those neurons do 
not constitutively express these kinases within degenerating neurons (Mailliot C et al., 1998). 
Class IV: Tau isoform lacking exon 2, 3 and 10 principally aggregate 
This group is represented by a single neurological disorder: myotonic dystrophy (DM) of 
types I and II (figure 5). DM is the commonest form of adult-onset muscular dystrophy. 
Genetically it is an inherited autosomal dominant disorder caused by a single gene mutation 
consisting of expansion of a CTG trinucleotide motif in the 3V untranslated of the myotonic 
dystrophy protein kinase gene (DMPK), located on chromosome 19q. It is a multisystemic 
disease affecting many systems as the central nervous system (cognitive and 
neuropsychiatric impairments), the heart, the genital tract, the eyes, the ears, gastrointestinal 
tract, endocrine system, thus leading to a wide and variable complex panel of symptoms 
(Meola G, 2000). Cognitive impairments, as memory, visuo-spatial recall and verbal scale, 
cortical atrophy essentially of the frontal and the temporal lobe and white matter lesions are 
often described in both DM1 and DM2 (Sansone V et al., 2007). 
Neuropathological lesions, as neurofibrillary tangles (NFTs), have been observed in adult 
DM1 individuals aged over 50 years. The pathological tau profile of DM1 is characterized by 
a strong pathological tau band at 60 kDa and, to a lesser extent, a pathological tau 
component at 64 and 69 kDa. This typical pathological tau profile is reflected by a reduced 
number of tau isoforms expressed in the brain of individuals with DM1, both at the protein 
and mRNA levels (Sergeant N et al., 2001). In addition, tau protein expression is also 
demonstrated to be altered in transgenic mice with human DM1 locus (Gomes-Pereira M et 
al., 2007). Using specific immunological probes against exon 2 and exon 3 corresponding 
amino acid sequences, the neurofibrillary lesions were shown to be devoid of tau isoforms 
with amino-terminal inserts (Maurage CA et al., 2005). An altered splicing of tau 
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characterized by a reduced expression of tau isoforms containing the amino-terminal inserts 
characterizes both DM1 and DM2. Overall, it demonstrates that the central nervous system 
is affected and that DMs are real tauopathies (Dhaenens CM et al., 2011). The direct 
relationship between the altered splicing of tau and NFD in DM remains to be established. 
Indeed, such an altered splicing of tau is commonly observed in FTDP- 17 and considered as 
reminiscent to NFD and tauopathies. 
5. Use of proteomics to investigate the mechanisms leading to Tauopathies 
Induction of tau fibrillization in cells remain unsatisfactory, this is a limiting factor since 
NFD cannot be totally reproduced in vitro (Sibille N et al., 2006). The development of in vivo 
models has provided an important tool to precise sequence of molecular events leading to 
tau aggregation. The use of proteomics in these transgenic animals has permitted to go 
further in the uncovering of the cellular and molecular pathways involved in NFD 
spreading within the brain and its relationship with the clinical expression of neurological 
disorders. In this section we will focus on the overexpresion either several isoforms of tau 
protein or mutated forms in animal models. 
5.1 Tau models 
Several animal models have been created to recapitulate the two main hallmarks of AD, 
refearing as amyloid plaques and PHFs. Despite the numerous models existing to mimic the 
features of this disease, none of them cover all the neuropathological, biochemical and 
behaviour alterations so far. There are models focus on overexpression of APP and/or 
presenilin containing one or more mutations linked to familial AD but they do not present 
NFD. Inspite tau mutations have not been described in AD patients, mutations in tau result 
in NFTs in an inherited form of FTDP and this dysfunction can lead to neurodegeneration 
and dementia. Taking into account that AD is a complex disorder and the perfect model 
does not exist, the large number of tau transgenic models with their strengths and 
weaknesses may allow for both understanding tau pathology and developing innovative 
therapeutic strategies. Nowadays there are several transgenic models which own 
combination of mutant APP, presenilin and tau (Chin J 2011). However, this triple model 
presents the “limitation” that tau pathology cannot be studied independently of the amyloid 
effects (Sergeant N and Buée L 2011). 
5.1.1 Caenorhabditis elegans 
The nematode Caenorhabditis elegans is widely being used to study neurodegenerative 
disorders despite the evolutionary difference. C. elegans has a short lifespan and it is easy to 
manipulate genetically. Modelling tauopathies is achieved through pan-neuronal 
overexpression either wild-type or mutated tau leading to a progressive uncoordinated 
locomotion which is directly correlated with the nervous system alterations in worms. This 
model is very useful to identify new genetic targets (Wolozin B et al., 2011). Recent data 
point out that tau pathology may lead to specific interference with intracellular mechanisms 
of axonal outgrowth and pathfinding (Brandt R et al., 2009). 
5.1.2 Drosophila melanogaster 
Another model used is the fruitfly Drosophila melanogaster. Regarding tauopathies, many 
groups developed fruitfly models by overexpressing wild-type and mutant forms of human 
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tau. Transgenic fruitflies showed key features of tauopathies as tissue- and temporal-specific 
effects as adult onset, progressive neurodegeneration, early death, enhanced toxicity of 
mutant tau, accumulation of abnormal tau and relative anatomic selectivity coupled with 
differential effects of distinct tau isoforms (Papanikolopoulou K and Skoulakis EM, 2011). 
5.1.3 Zebrafish 
The novel use of the vertebrate zebrafish as a model system for AD research offers a 
powerful platform for genetic and chemical screens as well as developmental studies 
(Tomasiewicz HG et al., 2002). The transgenic expression of the human tau mutation P301L 
in zebrafish neurons by Gal4/UAS–based vector system recapitulates most pathological 
features of tauopathies as abnormally phosphorylated reactivity with the epitopes AT180, 
AT270, 12E8, PHF1, 422, and AT8 in spinal cord neurons, aggregation and behavioral 
impairments (Paquet D et al., 2010). Application of inhibitors of human GSK3β reduced tau 
phosphorylation showing that zebrafish kinases are sufficiently conserved with respect to 
their human orthologues. Current evidence point out that zebrafish tau models recapitulate 
pathological and biochemical events that occur in tauopathies and therefore may be useful 
tools for further studies in the aetiology of dementia (Bai Q and Burton EA, 2011). 
5.1.4 Tau knock out mice and transgenic mice with wild-type human Tau 
Tau mouse models where tau expression is suppressed by MAPT deletion or invalidation 
present no major changes and animals are physiologically normal (Harada A et al., 1994). It 
seems other microtubule-associated proteins such as MAP1A probably compensate tau 
deficiency. Among the mice models available with wild-type human tau it is remarkable to 
note that overexpression of 3R tau isoforms lead to an accumulation of 
hyperphosphorylated tau proteins in spinal cord neurons and axonal degeneration as well 
as a reduction in axonal transport (Brion JP et al., 1999). Similar data were observed in 
transgenic mice expressing the longest human brain tau isoform under the control of the 
human Thy-1 promoter. Hyperphosphorylated human tau protein was present in nerve cell 
bodies, axons and dendrites (Gotz J et al., 1995). Furthermore, recent studies in transgenic 
mouse models that express the entire human MAPT gene in the presence and absence of the 
mouse Mapt gene show differences between mouse and human tau in the regulation of exon 
10 inclusion during development and in the young adult. In addition, it was observed 
species-specific variations in the expression of 3R- and 4R-tau within the frontal cortex and 
hippocampus during the development as well as in cell distribution of the isoforms 
(McMillan P et al., 2008). 
5.1.5 Transgenic mice with mutated human Tau 
Mutated tau transgenes have been used under various promoters (2’,3’-cyclic nucleotide 3’-
phosphodiesterase, CaMKII, PDGF, Prion, or Thy1.2) with or without inducible systems. 
The most common phenotype of transgene tau animal is the motor alterations. Tau 
transgenic mice rTg4510 present P301L mutation in an inductible way and develop NFTs, 
neuronal loss and behavioural impairments (Santacruz K et al., 2005). Nonetheless the 
suppression of the expression of this mutated tau revers behavioural impairements despite 
the NFTs formation keeps on, indeed it seems soluble tau rather than NFTs may be 
deleterious. These observations are in agreement with a recent report in which brain extract 
injection from mutant P301S tau expressing mice into brain of transgenic wild-type tau-
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expressing animals induces assembly of wild-type human tau into filaments and spreading 
of pathology from the site of injection to neighbouring brain regions (Clavaguera et al., 
2009). 
Another transgenic mice model is TauRD/∆K280 that expresses only the 4R tau domains 
and carry the ∆K280 mutation with a deletion of the amino- and carboxy terminal regions of 
tau protein. This mutation leads to tau aggregation followed by astrogliosis and neuronal 
loss. When the transgene is switched off the aggregation of the exogenous tau disappears 
within around one month and a haf and only aggregated murine tau proteins remain acting 
as a nucleation factor for tau aggregation (Mocanu MM et al., 2008). Other study suggest a 
“prion –like” propagation since aggregation continues even if the original tau species have 
disappeared (Sydow A and Mandelkov EM, 2010). 
The K3 transgenic mouse strain expresses human tau carrying the K369I mutation under the 
Thy1 promoter (Ittner LM et al., 2008). This tau mutation was found in a family of patients 
presenting with Pick’s disease without parkinsonism and amyotrophy (Neumann M et al., 
2001). The transgenic mice present early-onset memory impairment and amyotrophy in the 
absence of overt neurodegeneration. Tau transgene is mainly expressed in the substantia 
nigra and such expression leads to an early-onset parkinsonism phenotype. Interestingly, 
motor performance of young, but not old K3 mice improves upon L-dopa treatment. 
Amyotrophy is probable to be related to tau expression in the sciatic nerve in the same way 
as in Tg30tau model where pathogenic mutations (P301S and G272V) are expressed in the 
forebrain and the spinal cord showing progressive motor impairment with neurogenic 
muscle atrophy besides the hippocampal atrophy (Leroy K et al., 2007). Moreover, 
transgenic mouse model overexpressing human 1N4R double-mutant tau (P301S and 
G272V) and invalidated endogenous TAU gene show an accelerated human mutant tau 
aggregation (Ando K et al., 2011) suggesting that murine tau proteins may act as inhibitors 
of tau aggregation. 
Thy-Tau22 mouse transgenic line exhibits progressive neuron-specific AD-like tau 
pathology devoid of any motor deficits (Schindowski K et al., 2006). In addition to 
neurofibrillary tangle-like inclusions and mild astrogliosis, this model shows hyper- and 
abnormally phosphorylated tau on several Alzheimer’s disease-relevant tau epitopes that 
accumulates within the somato-dendritic area in the hippocampus (Schindowski K et al., 
2008). A progressive development of NFTs is observed in the hippocampus and amygdala, 
which parallels behavioural impairments as well as electrophysiological alterations (Van der 
Jeugd et al., 2011). These latter changes are observed despite any striking loss of 
neuronal/synaptic markers until 12 months of age in the hippocampus. Interestingly, at that 
time point, THY-Tau22 mice exhibit septo-hippocampal tau pathology accompanied by 
altered retrograde transport from hippocampus to medial septum (Belarbi K et al., 2009) 
with an accumulation of the nerve growth factor (NGF) levels in the hippocampus 
consistent with a decrease of its uptake or retrograde transport by cholinergic terminals 
(Belarbi K et al., in press). Recent data indicate that voluntary exercise prevented memory 
alterations in these transgenic mice and increased mRNA levels of genes involved in 
cholesterol trafficking such as NPC1 and NPC2 (Belarbi K et al., 2011). 
6. Tau proteins as biomarkers of Tauopathies 
Searching for biomarkers is one of the most challenges in current medicine. Biomarkers 
must be not only specific for a single pathology but also indicative of its progression 
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(Mayeux R et al., 2011). This is extremely complex in diseases concerning elderly since many 
symptoms are common and indistinguishable among them as the dementia sign. It is 
compulsory to find proteins and their post-translational modifications that may provide 
accuracy on the early diagnosis of the disease and eventually could serve as a therapeutic 
target. Successfully the development in neuroimaging techniques enables to facilitate and 
establish a preliminary diagnosis of different neurodegenerative disorders. 
Focusing on tauopathies, the presence of tau in CSF was first described in 1993. In AD, tau 
inclusions in the brain associated with neuronal damages lead to the leakage of abnormal 
forms of tau in the CSF resulting in quantitative and qualitative changes in CSF-tau 
composition. Numerous studies demonstrated increased CSF total tau and phosphorylated 
tau levels in AD, with mean levels 2-3 times higher compared to healthy controls. Tau is 
now a validated biomarker for AD, it improves the clinical diagnostic accuracy and its 
assessment for AD diagnosis is now proposed (Dubois B et al., 2010). As the brain lesions 
develop very early during the disease course even before the first clinical symptoms appear, 
CSF tau is not only a useful diagnostic marker in the advanced stages of the disease but also 
a usefull predictive marker in the earliest stages when clinical expression is weak (Hertze J 
et al., 2010). However, for differential diagnosis of dementia, the actually available tests 
measuring tau and phosphorylated tau levels in CSF are not sufficient and the identification 
of more specific postranslational modifications of tau in AD by proteomic approaches is 
needed. In the future, for the use of tau as biomarker in large clinical trials or in clinical 
practice, one important goal will be to develop sensitive methods to detect the very low 
concentration of tau in the blood (<1 pMol). Therefore, sample pre-treatment and handling 
will be crucial in developing a reliable tau assay in blood/plasma. 
7. Conclusion 
Tau is a neuronal protein that promotes neuronal survival, it is essentially located within the 
axonal and indispensable for the organization, stabilization, and dynamics of microtubules. 
The interaction between tau and microtubules is regulated by phosphorylation. It is widely 
reported that abnormally and hyperphosphorylated tau proteins lead to insoluble 
aggregates. The presence of these aggregates is clinically correlated with cognitive decline in 
a process called NFD; this event common to more than twenty diseases is referred as 
tauopathies. 
The development of the proteomics era has achieved to go further in the characterization of 
tauopathies and shed light to the mechanism involved in their aetiology. Proteomics 
approaches as chromatography, mono- and bi-dimensional gel electrophoresis have reached 
to separate proteins with a quite high resolution after fractioning precedures, selecting a 
concrete population of cells or organelle isolation. The use of additional reagents to the 
extraction buffer such as detergents and the evolution of concomitant technologies as 
microscopy have provided a broad spectrum to characterize the structure and size of a large 
number of biological complex samples. The combination of protein separation methods with 
fluorescence dyes and radioactive isotopes (ICAT, iTRAQ, SILAC) makes possible not only 
more sensitive and reproducible results but also provides a quantitative analysis among 
samples (2D-DIGE, LC-MS, SELDI). 
The previous hallmark is extremely linked to the identification of the separated or isolated 
proteins. MS has provided the composition of the molecules and also their post-translational 
modifications since changes in amino acid residues may be identified and characterized by 
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MS/MS, Peptide Mass Fingerprinting and NMR. The utilization of the current available 
ionization sources as ESI and MALDI coupled to mass analysers mainly TOF allows almost 
any compound to be analysed by MS at low levels in complex mixtures. Furthermore, there 
are a large number of software tools dedicated to facilitate raw data processing, database-
dependent search, statistical evaluation of the search result, quantitative algorithms and 
statistical analysis of quantitative data. 
The generation of animal models helps to elucidate the genetic and proteomics aspects 
involved during the origin and development of tauopathies. Only by the knowledge of the 
different components of the disease and their contribution, it will be possible to proceed in 
the right way. 
In summary, numerous proteomics approaches are available in order to accomplish new 
perspectives in the neurodegenerative disorders field. At the moment there are many 
studies focused on finding out the functions of tau protein thoughtout proteomics 
approaches. Proteomics methods allow to uncover the different signaling pathways 
involved in tau biology, proteomics data are intimately related to the protein state: post-
translational modifications, cleavage, conformation, synthesis, degradation and activity (if it 
is known). The selection of the different techniques depends on the aim of the research: 
protein identification, de novo peptide sequencing, and identification of post-translational 
modifications or determination of protein-protein interactions. Understanding the human 
proteome and its variations in physiological and pathological conditions will be intimately 
related to uncover cellular and molecular pathways involved in the aetiology and 
progression of the tauopathies as well as to identify potential targets for drug design. 
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